QUINTESSENTIAL: A multicenter phase 2 study evaluating the efficacy and safety of arlocabtagene autoleucel (arlo-cel) in triple- and quad-class exposed patients with relapsed or refractory multiple myeloma (RRMM).Krina K. Patel, Ciara L. Freeman, Susan Bal et al.|Journal of Clinical Oncology|2025Cited by 1
Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)Ciara Louise Freeman, Krina K. Patel, Sarah Larson et al.|Blood|2025Cited by 1
MM-1157: Trial in Progress: Quintessential—A Phase 2 Study of Arlocabtagene Autoleucel in Triple- and Quad-Class Exposed Patients With Relapsed and Refractory Multiple MyelomaKrina Patel, Ciara L. Freeman, Sarah Larson et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
Trial in Progress: QUINTESSENTIAL—A Phase 2 Study of Arlocabtagene Autoleucel (arlo-cel) in Triple- and Quad-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma (RRMM)Krina Patel, Ciara L. Freeman, Sarah Larson et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)Susan Bal, Sham Mailankody, Luciano J. Costa et al.|Blood|2025Cited by 0